Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice.
PKG
cGMP
cinaciguat
diabetic nephropathy
mesangial cells
sGC activator
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
17
02
2021
received:
19
10
2020
accepted:
19
02
2021
pubmed:
3
3
2021
medline:
7
5
2022
entrez:
2
3
2021
Statut:
ppublish
Résumé
Diabetic nephropathy is the leading cause for end-stage renal disease worldwide. Until now, there is no specific therapy available. Standard treatment with inhibitors of the renin-angiotensin system just slows down progression. However, targeting the NO/sGC/cGMP pathway using sGC activators does prevent kidney damage. Thus, we investigated if the sGC activator cinaciguat was beneficial in a mouse model of diabetic nephropathy, and we analysed how mesangial cells (MCs) were affected by related conditions in cell culture. Type 1 diabetes was induced with streptozotocin in wild-type and endothelial NOS knockout (eNOS KO) mice for 8 or 12 weeks.. Half of these mice received cinaciguat in their chow for the last 4 weeks. Kidneys from the diabetic mice were analysed with histochemical assays and by RT-PCR and western blotting. . Additionally, primary murine MCs under diabetic conditions were stimulated with 8-Br-cGMP or cinaciguat to activate the sGC/cGMP pathway. The diabetic eNOS KO mice developed most characteristics of diabetic nephropathy, most marked at 12 weeks. Treatment with cinaciguat markedly improved GFR, serum creatinine, mesangial expansion and kidney fibrosis in these animals. We determined expression levels of related signalling proteins. Thrombospondin 1, a key mediator in kidney diseases, was strongly up-regulated under diabetic conditions and this increase was suppressed by activation of sGC/cGMP signalling. Activation of the NO/sGC/PKG pathway with cinaciguat was beneficial in a model of diabetic nephropathy. Activators of sGC might be an appropriate therapy option in patients with Type 1 diabetes. This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc.
Sections du résumé
BACKGROUND AND PURPOSE
Diabetic nephropathy is the leading cause for end-stage renal disease worldwide. Until now, there is no specific therapy available. Standard treatment with inhibitors of the renin-angiotensin system just slows down progression. However, targeting the NO/sGC/cGMP pathway using sGC activators does prevent kidney damage. Thus, we investigated if the sGC activator cinaciguat was beneficial in a mouse model of diabetic nephropathy, and we analysed how mesangial cells (MCs) were affected by related conditions in cell culture.
EXPERIMENTAL APPROACH
Type 1 diabetes was induced with streptozotocin in wild-type and endothelial NOS knockout (eNOS KO) mice for 8 or 12 weeks.. Half of these mice received cinaciguat in their chow for the last 4 weeks. Kidneys from the diabetic mice were analysed with histochemical assays and by RT-PCR and western blotting. . Additionally, primary murine MCs under diabetic conditions were stimulated with 8-Br-cGMP or cinaciguat to activate the sGC/cGMP pathway.
KEY RESULTS
The diabetic eNOS KO mice developed most characteristics of diabetic nephropathy, most marked at 12 weeks. Treatment with cinaciguat markedly improved GFR, serum creatinine, mesangial expansion and kidney fibrosis in these animals. We determined expression levels of related signalling proteins. Thrombospondin 1, a key mediator in kidney diseases, was strongly up-regulated under diabetic conditions and this increase was suppressed by activation of sGC/cGMP signalling.
CONCLUSION AND IMPLICATIONS
Activation of the NO/sGC/PKG pathway with cinaciguat was beneficial in a model of diabetic nephropathy. Activators of sGC might be an appropriate therapy option in patients with Type 1 diabetes.
LINKED ARTICLES
This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc.
Substances chimiques
Benzoates
0
Nitric Oxide
31C4KY9ESH
BAY 58-2667
329773-35-5
Guanylate Cyclase
EC 4.6.1.2
Soluble Guanylyl Cyclase
EC 4.6.1.2
Cyclic GMP
H2D2X058MU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2460-2475Informations de copyright
© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 176, S21-S141. https://doi.org/10.1111/bph.14748
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176, S297-S396. https://doi.org/10.1111/bph.14752
Alexander, S. P. H., Roberts, R. E., Broughton, B. R. S., Sobey, C. G., George, C. H., Stanford, S. C., Cirino, G., Docherty, J. R., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Mangum, J., Wonnacott, S., & Ahluwalia, A. (2018). Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of pharmacology. British Journal of Pharmacology, 175, 407-411. https://doi.org/10.1111/bph.14112
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). Diabetic kidney disease: Challenges, progress, and possibilities. Clinical Journal of the American Society of Nephrology, 12, 2032-2045. https://doi.org/10.2215/CJN.11491116
Bähre, H., & Kaever, V. (2017). Mass spectrometric analysis of non-canonical cyclic nucleotides. Handbook of Experimental Pharmacology, 238, 293-306. https://doi.org/10.1007/164_2016_5001
Boustany-Kari, C. M., Harrison, P. C., Chen, H., Lincoln, K. A., Qian, H. S., Clifford, H., Wang, H., Zhang, X., Gueneva-Boucheva, K., Bosanac, T., Wong, D., Fryer, R. M., Richman, J. G., Sarko, C., & Pullen, S. S. (2016). A soluble guanylate cyclase activator inhibits the progression of diabetic nephropathy in the ZSF1 rat. The Journal of Pharmacology and Experimental Therapeutics, 356, 712-719. https://doi.org/10.1124/jpet.115.230706
Brenner, B. M., Cooper, M. E., de, Z. D., Keane, W. F., Mitch, W. E., Parving, H. H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England Journal of Medicine, 345, 861-869. https://doi.org/10.1056/NEJMoa011161
Breyer, M. D., Böttinger, E., Brosius, F. C., Coffman, T. M., Harris, R. C., Heilig, C. W., Sharma, K., & AMDCC. (2005). Mouse models of diabetic nephropathy. Journal of the American Society of Nephrology, 16, 27-45. https://doi.org/10.1681/ASN.2004080648
Chaykovska, L., Heunisch, F., von Einem, G., Hocher, C.-F., Tsuprykov, O., Pavkovic, M., Sandner, P., Kretschmer, A., Chu, C., Elitok, S., Stasch, J. P., & Hocher, B. (2018). Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium. PLoS ONE, 13, e0195828. https://doi.org/10.1371/journal.pone.0195828
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Sobey, C. G., Stanford, S. C., Teixeira, M. M., Wonnacott, S., & Ahluwalia, A. (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. British Journal of Pharmacology, 175(7), 987-993. https://doi.org/10.1111/bph.14153
Czirok, S., Fang, L., Radovits, T., Szabó, G., Szénási, G., Rosivall, L., Merkely, B., & Kökény, G. (2017). Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ß expression in type-1 diabetic rats. Scientific Reports, 7, 11218. https://doi.org/10.1038/s41598-017-10125-3
Dong, J., Ping, Y., Wang, Y., & Zhang, Y. (2018). The roles of endothelial nitric oxide synthase gene polymorphisms in diabetes mellitus and its associated vascular complications: A systematic review and meta-analysis. Endocrine, 62, 412-422. https://doi.org/10.1007/s12020-018-1683-4
Elgert, C., Rühle, A., Sandner, P., & Behrends, S. (2019). A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGC. Biochemical Pharmacology, 163, 142-153. https://doi.org/10.1016/j.bcp.2019.02.007
Erdmann, E., Semigran, M. J., Nieminen, M. S., Gheorghiade, M., Agrawal, R., Mitrovic, V., & Mebazaa, A. (2013). Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. European Heart Journal, 34, 57-67. https://doi.org/10.1093/eurheartj/ehs196
Farkas, K., Jermendy, G., Herold, M., Ruzicska, E., Sasvári, M., & Somogyi, A. (2004). Impairment of the NO/cGMP pathway in the fasting and postprandial state in type 1 diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes, 112, 258-263. https://doi.org/10.1055/s-2004-817973
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, 39, 175-191. https://doi.org/10.3758/BF03193146
Fleige, S., Walf, V., Huch, S., Prgomet, C., Sehm, J., & Pfaffl, M. W. (2006). Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnology Letters, 28, 1601-1613. https://doi.org/10.1007/s10529-006-9127-2
Furman, B. L. (2015). Streptozotocin-induced diabetic models in mice and rats. Current Protocols in Pharmacology, 70, 5.47.1-5.47.20. https://doi.org/10.1002/0471141755.ph0547s70
Gheorghiade, M., Greene, S. J., Filippatos, G., Erdmann, E., Ferrari, R., Levy, P. D., Maggioni, A., Nowack, C., Mebazaa, A., & on behalf of the COMPOSE Investigators and Coordinators. (2012). Cinaciguat, a soluble guanylate cyclase activator: Results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. European Journal of Heart Failure, 14, 1056-1066. https://doi.org/10.1093/eurjhf/hfs093
Hoffmann, L. S., Kretschmer, A., Lawrenz, B., Hocher, B., & Stasch, J.-P. (2015). Chronic activation of Heme free guanylate cyclase leads to renal protection in dahl salt-sensitive rats. PLoS ONE, 10, e0145048. https://doi.org/10.1371/journal.pone.0145048
Hugo, C., & Daniel, C. (2009). Thrombospondin in renal disease. Nephron. Experimental Nephrology, 111, e61-e66. https://doi.org/10.1159/000198235
IDF DIABETES ATLAS: Eighth edition. 2017 2017.
Islam, M. Z., van Dao, C., Miyamoto, A., & Shiraishi, M. (2017). Rho-kinase and the nitric oxide pathway modulate basilar arterial reactivity to acetylcholine and angiotensin II in streptozotocin-induced diabetic mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 390, 929-938. https://doi.org/10.1007/s00210-017-1396-x
Jha, J. C., Ho, F., Dan, C., & Jandeleit-Dahm, K. (2018). A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. Clinical Science, 132, 1811-1836. https://doi.org/10.1042/CS20171459
Kalk, P., Godes, M., Relle, K., Rothkegel, C., Hucke, A., Stasch, J.-P., & Hocher, B. (2006). NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. British Journal of Pharmacology, 148, 853-859. https://doi.org/10.1038/sj.bjp.0706792
Kashihara, N., Haruna, Y., Kondeti, V. K., & Kanwar, Y. S. (2010). Oxidative stress in diabetic nephropathy. Current Medicinal Chemistry, 17, 4256-4269. https://doi.org/10.2174/092986710793348581
Khamaisi, M., Keynan, S., Bursztyn, M., Dahan, R., Reinhartz, E., Ovadia, H., & Raz, I. (2006). Role of renal nitric oxide synthase in diabetic kidney disease during the chronic phase of diabetes. Nephron. Physiology, 102, p72-p80. https://doi.org/10.1159/000089946
Krishnan, S. M., Kraehling, J. R., Eitner, F., Bénardeau, A., & Sandner, P. (2018). The impact of the nitric oxide (NO)/soluble guanylyl cyclase (sGC) signaling cascade on kidney health and disease: A preclinical perspective. International Journal of Molecular Sciences, 19(6), 1712. https://doi.org/10.3390/ijms19061712
Lee, D. I., Zhu, G., Sasaki, T., Cho, G.-S., Hamdani, N., Holewinski, R., Jo, S. H., Danner, T., Zhang, M., Rainer, P. P., Bedja, D., Kirk, J. A., Ranek, M. J., Dostmann, W. R., Kwon, C., Margulies, K. B., van Eyk, J. E., Paulus, W. J., Takimoto, E., & Kass, D. A. (2015). Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature, 519, 472-476. https://doi.org/10.1038/nature14332
Levin A., Tonelli M., Bonventre J., Coresh J., Donner J. A., Fogo A. B., Fox C. S., Gansevoort R. T., Heerspink H. J. L., Jardine M., Kasiske B., Köttgen A., Kretzler M., Levey A. S., Luyckx V. A., Mehta R., Moe O., Obrador G., Pannu N., Parikh C. R., Perkovic V., Pollock C., Stenvinkel P., Tuttle K. R., Wheeler D. C., Eckardt K. U., ISN Global Kidney Health Summit participants (2017). Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. The Lancet, 390(10105), 1888-1917. https://doi.org/10.1016/S0140-6736(17)30788-2
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. The New England Journal of Medicine, 329, 1456-1462. https://doi.org/10.1056/NEJM199311113292004
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001). Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England Journal of Medicine, 345, 851-860. https://doi.org/10.1056/NEJMoa011303
Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P. H., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Sobey, C. G., Stefanska, B., Stephens, G., Teixeira, M., & Ahluwalia, A. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British Journal of Pharmacology, 177, 3611-3616. https://doi.org/10.1111/bph.15178
Malek, V., Sharma, N., & Gaikwad, A. B. (2019). Histone acetylation regulates natriuretic peptides and neprilysin gene expressions in diabetic cardiomyopathy and nephropathy. Current Molecular Pharmacology, 12, 61-71. https://doi.org/10.2174/1874467212666181122092300
Maslanka Figueroa, S., Fleischmann, D., Beck, S., Tauber, P., Witzgall, R., Schweda, F., & Goepferich, A. (2020). Nanoparticles mimicking viral cell recognition strategies are superior transporters into mesangial cells. Advanced Science (Weinh), 7, 1903204. https://doi.org/10.1002/advs.201903204
Matata, B. M., & Galiñanes, M. (2001). Effect of diabetes on nitric oxide metabolism during cardiac surgery. Diabetes, 50, 2603-2610. https://doi.org/10.2337/diabetes.50.11.2603
Mátyás, C., Németh, B. T., Oláh, A., Hidi, L., Birtalan, E., Kellermayer, D., Ruppert, M., Korkmaz-Icöz, S., Kökény, G., Horváth, E. M., Szabó, G., Merkely, B., & Radovits, T. (2015). The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus. Cardiovascular Diabetology, 14, 145. https://doi.org/10.1186/s12933-015-0309-x
Mehanna, O. M., El Askary, A., Al-Shehri, S., & El-Esawy, B. (2018). Effect of phosphodiesterase inhibitors on renal functions and oxidant/antioxidant parameters in streptozocin-induced diabetic rats. Archives of Physiology and Biochemistry, 124, 424-429. https://doi.org/10.1080/13813455.2017.1419267
Miller, T. W., Isenberg, J. S., & Roberts, D. D. (2010). Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase. British Journal of Pharmacology, 159, 1542-1547. https://doi.org/10.1111/j.1476-5381.2009.00631.x
Moore, K. B., McKenna, K., Osman, M., Tormey, W. P., McDonald, D., & Thompson, C. J. (2007). Atrial natriuretic peptide increases urinary albumin excretion in people with normoalbuminuric type-2 diabetes. Irish Journal of Medical Science, 176, 67-73. https://doi.org/10.1007/s11845-007-0030-1
Nakagawa, T., Sato, W., Glushakova, O., Heinig, M., Clarke, T., Campbell-Thompson, M., Yuzawa, Y., Atkinson, M. A., Johnson, R. J., & Croker, B. (2007). Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. Journal of the American Society of Nephrology, 18, 539-550. https://doi.org/10.1681/ASN.2006050459
Nakayama, T., Sato, W., Kosugi, T., Zhang, L., Campbell-Thompson, M., Yoshimura, A., Croker, B. P., Johnson, R. J., & Nakagawa, T. (2009). Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in the mouse. American Journal of Physiology-Renal Physiology, 296(2), F317-F327. https://doi.org/10.1152/ajprenal.90450.2008
Nguyen, T. Q., & Goldschmeding, R. (2019). The mesangial cell in diabetic nephropathy. In J. J. Roelofs & L. Vogt (Eds.), Diabetic nephropathy. Pathophysiology and clinical aspects. Cham (pp. 143-151). Switzerland: Springer. https://doi.org/10.1007/978-3-319-93521-8_9
Obineche, E., Chandranath, I., Adeghate, E., Benedict, S., Fahim, M., & Adem, A. (2006). Alterations in atrial natriuretic peptide and its receptor levels in long-term, streptozotocin-induced, diabetes in rats. Annals of the New York Academy of Sciences, 1084, 223-234. https://doi.org/10.1196/annals.1372.025
Parving, H. H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001). The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. The New England Journal of Medicine, 345, 870-878. https://doi.org/10.1056/NEJMoa011489
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., Maccallum, C. J., Macleod, M., … Würbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410
Pofi, R., Fiore, D., de Gaetano, R., Panio, G., Gianfrilli, D., Pozza, C., Barbagallo, F., Xiang, Y. K., Giannakakis, K., Morano, S., Lenzi, A., Naro, F., Isidori, A. M., & Venneri, M. A. (2017). Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7. Scientific Reports, 7, 44584. https://doi.org/10.1038/srep44584
Sandner, P., Zimmer, D. P., Todd Milne, G. T., Follmann, M., Hobbs, A., & Stasch, J. P. (2021). Soluble guanylate cyclase stimulators and activators. Handbook of Experimental Pharmacology, 264, 355-394. https://doi.org/10.1007/164_2018_197
Scheele, W., Diamond, S., Gale, J., Clerin, V., Tamimi, N., Le, V., Walley, R., Grover-Páez, F., Perros-Huguet, C., Rolph, T., & El Nahas, M. (2016). Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy. Journal of the American Society of Nephrology, 27, 3459-3468. https://doi.org/10.1681/ASN.2015050473
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J. Y., White, D. J., Hartenstein, V., Eliceiri, K., Tomancak, P., & Cardona, A. (2012). Fiji: An open-source platform for biological-image analysis. Nature Methods, 9, 676-682. https://doi.org/10.1038/nmeth.2019
Schinner, E., Schramm, A., Kees, F., Hofmann, F., & Schlossmann, J. (2013). The cyclic GMP-dependent protein kinase Iα suppresses kidney fibrosis. Kidney International, 84, 1198-1206. https://doi.org/10.1038/ki.2013.219
Schinner, E., Wetzl, V., Schramm, A., Kees, F., Sandner, P., Stasch, J.-P., Hofmann, F., & Schlossmann, J. (2017). Inhibition of the TGFβ signalling pathway by cGMP and cGMP-dependent kinase I in renal fibrosis. FEBS Open Bio, 7, 550-561. https://doi.org/10.1002/2211-5463.12202
Schlöndorff, D., & Banas, B. (2009). The mesangial cell revisited: No cell is an island. Journal of the American Society of Nephrology, 20, 1179-1187. https://doi.org/10.1681/ASN.2008050549
Schramm, A., Schweda, F., Sequeira-Lopez, M. L. S., Hofmann, F., Sandner, P., & Schlossmann, J. (2019). Protein kinase G is involved in acute but not in long-term regulation of renin secretion. Frontiers in Pharmacology, 10, 800. https://doi.org/10.3389/fphar.2019.00800
Stasch, J.-P., Schlossmann, J., & Hocher, B. (2015). Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. Current Opinion in Pharmacology, 21, 95-104. https://doi.org/10.1016/j.coph.2014.12.014
Stasch, J.-P., Schmidt, P. M., Nedvetsky, P. I., Nedvetskaya, T. Y., H.S., A. K., Meurer, S., Deile, M., Taye, A., Knorr, A., Lapp, H., Müller, H., Turgay, Y., Rothkegel, C., Tersteegen, A., Kemp-Harper, B., Müller-Esterl, W., & Schmidt, H. H. H. W. (2006). Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. Journal of Clinical Investigation, 116(9), 2552-2561. https://doi.org/10.1172/jci28371
Takahashi, T., & Harris, R. C. (2014). Role of endothelial nitric oxide synthase in diabetic nephropathy: Lessons from diabetic eNOS knockout mice. Journal Diabetes Research, 2014590541, 1-17. https://doi.org/10.1155/2014/590541
Takemoto, M., Asker, N., Gerhardt, H., Lundkvist, A., Johansson, B. R., Saito, Y., & Betsholtz, C. (2002). A new method for large scale isolation of kidney glomeruli from mice. The American Journal of Pathology, 161, 799-805. https://doi.org/10.1016/S0002-9440(10)64239-3
Tervaert, T. W. C., Mooyaart, A. L., Amann, K., Cohen, A. H., Cook, H. T., Drachenberg, C. B., Ferrario, F., Fogo, A. B., Haas, M., de Heer, E., Joh, K., Noël, L. H., Radhakrishnan, J., Seshan, S. V., Bajema, I. M., Bruijn, J. A., & on behalf of the Renal Pathology Society. (2010). Pathologic classification of diabetic nephropathy. Journal of the American Society of Nephrology, 21, 556-563. https://doi.org/10.1681/ASN.2010010010
Tessari, P. (2015). Nitric oxide in the normal kidney and in patients with diabetic nephropathy. Journal of Nephrology, 28, 257-268. https://doi.org/10.1007/s40620-014-0136-2
Tessari, P., Cecchet, D., Cosma, A., Vettore, M., Coracina, A., Millioni, R., Iori, E., Puricelli, L., Avogaro, A., & Vedovato, M. (2010). Nitric oxide synthesis is reduced in subjects with type 2 diabetes and nephropathy. Diabetes, 59, 2152-2159. https://doi.org/10.2337/db09-1772
Tung, C.-W., Hsu, Y.-C., Shih, Y.-H., Chang, P.-J., & Lin, C.-L. (2018). Glomerular mesangial cell and podocyte injuries in diabetic nephropathy. Nephrology (Carlton), 23(Suppl 4), 32-37. https://doi.org/10.1111/nep.13451
Umanath, K., & Lewis, J. B. (2018). Update on diabetic nephropathy: Core curriculum 2018. American Journal of Kidney Diseases, 71, 884-895. https://doi.org/10.1053/j.ajkd.2017.10.026
Wang, S., Skorczewski, J., Feng, X., Mei, L., & Murphy-Ullrich, J. E. (2004). Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-beta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. The Journal of Biological Chemistry, 279, 34311-34322. https://doi.org/10.1074/jbc.M401629200
Wetzl, V., Schinner, E., Kees, F., Hofmann, F., Faerber, L., & Schlossmann, J. (2016). Involvement of cyclic guanosine monophosphate-dependent protein kinase I in renal antifibrotic effects of serelaxin. Frontiers in Pharmacology, 7, 195. https://doi.org/10.3389/fphar.2016.00195
Wolf, G., Chen, S., & Ziyadeh, F. N. (2005). From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy. Diabetes, 54, 1626-1634. https://doi.org/10.2337/diabetes.54.6.1626